组织工程与重建外科杂志

组织工程与重建外科杂志 ›› 2010, Vol. 6 ›› Issue (5): 257-260.doi: 10.3969/j.issn.1673-0364.2010.05.005

• 论著 • 上一篇    下一篇

脐带间充质干细胞治疗脊髓小脑性共济失调及多系统萎缩小脑型临床分析

刘静，薛梅，朱玲，丁丽，阎洪敏，王志东，韩冬梅，郭子宽，王恒湘   

  1. 空军总医院血液科；北京放射与辐射医学研究所
  • 发布日期:2020-07-23

Clinical Analysis on the Treatment of Spinocerebellar Ataxia and Multiple System Atrophy-Cerebellar Type with Umbilical Cord Mesenchymal Stem Cells

LIU Jing1, XUE Mei1, ZHU Ling1, DING Li1, YAN Hongmin1, WANG Zhidong1, HAN Dongmei1, GUO Zikuan2, WANG Hengxiang1   

  1. 1 Department of Hematology, General Hospital of the Air Force, Beijing 100142,China;2 Department of Experimental Hematology,Beijing Institute of Radiation Medicine,Beijing 100850,China.
  • Published:2020-07-23
  • Contact: 首都发展基金重点项目(2007-2033)，国家高技术研究发展计划(863项目)(2007AA02Z454)，国家重大新药创制基金(2009ZX09503-019)

摘要： 目的观察脐带间充质干细胞（UC-MSC）鞘内注射,治疗脊髓小脑性共济失调（SCA）及多系统萎缩小脑型（MSA-C）的临床效果。方法 2009年10月至2010年9月,对14例SCA及10例MSA-C患者,给予UC-MSC鞘内注射治疗,每次1×106 cells/kg,1次/周,4次为1个疗程。其中3例SCA患者接受2个疗程,余均接受1个疗程。采用世界神经病联合会国际合作共济失调评分量表（ICARS）及日常生活量表（ADL）对患者治疗前后神经功能进行评定,分值越高表示神经功能缺损越严重。结果本组患者治疗后1个月与治疗前比较,ICARS及ADL明显降低（P<0.01）。除1例SCA患者治疗无效外,其余患者均有效,表现为行走和站立不稳、运动迟缓、上肢精细动作障碍、书写困难、构音障碍等临床症状得到改善。治疗后常见不良反应有头晕（4例）、腰痛（2例）、头痛（1例）,但均在1～3 d内自行消失。结论 UC-MSC鞘内注射治疗是安全的,可以一定程度地改善SCA及MSA-C患者的临床症状,提高患者生活质量。

关键词: 脐带间充质干细胞, 脊髓小脑性共济失调, 多系统萎缩

Abstract: Objective To observe the clinical effect of umbilical cord mesenchymal stem cells（UC-MSC） in the treatment of spinocerebellar ataxia（SCA） and multiple system atrophy-cerebellar type（MSA-C） by intrathecal injection.Methods From Oct 2009 to Sep 2010,14 cases with SCA and 10 cases of MSA-C were given UC-MSC by weekly intrathecal injection at a dose of 1×106 cells/kg for four times as a course.All the patients received 1 course of treatment except 3 cases received 2 cycles.The movement ability and the quality of daily life were evaluated with the International Cooperative Ataxia Rating Scale（ICARS） and Activity of Daily Living Scale（ADL） and the scores were compared with those before the treatment.Results The results showed that the scores were significantly decreased 1 month after treatment（P<0.01）.The symptoms,including unstable walking and standing,slow movement,upper limb fine motor disorders,writing difficulties and dysarthria,were greatly improved except one patient who had no response.The observed side effects included dizziness（4 patients）,back pains（2 cases） and headache（1 case）,which disappeared within 1-3 days.Conclusion UC-MSC implantation is safe,and able to ameliorate clinical symptoms and improve life quality of SCA and MSA-C patients to some extent as well.

Key words: Umbilical cord mesenchymal stem cells, Spinocerebellar ataxia, Multiple system atrophy

中图分类号: